Sanjieke, a China-based vocational training services provider, has secured over 200 million yuan ($30 million) in its Series B+ and C rounds of funding, while Beijing Immunochina Pharmaceutical has raised ‘tens of millions of US dollars’ led by China Life Healthcare Investment.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
